Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants

Pediatrics

Volumn 119, Issue 3, 2007, Pages

  D'Angio, Carl T ^a,d   Boohene, Paulina A ^a   Mowrer, Anne ^a   Audet, Susette ^b   Menegus, Marilyn A ^a   Schmid, D Scott ^c   Beeler, Judy A ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Humoral immunity; Immunization; Immunology; Measles mumps rubella vaccine; Premature infant; Vaccines; Varicella vaccine; Very low birth weight infant

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; GLYCOPROTEIN; IMMUNOGLOBULIN G; MEASLES ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CHICKENPOX; CHILD HEALTH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MALE; MEASLES; MUMPS; PREMATURITY; PRIORITY JOURNAL; RUBELLA; TERM BIRTH; VACCINATION;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS; REFERENCE VALUES; RUBELLA VIRUS;

EID: 33947151406     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2241     Document Type: Article

References (43)

1. American Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:67-103
2. Washburn LK, O'Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr. 1993;123:791-794
3. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis. 1994;170:76-81
4. Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics. 1995;96:216-219
5. Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003;88:206-210
6. Berrington JE, Cant AJ, Matthews JN, O'Keeffe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics. 2006;117(4). Available at: www.pediatrics.org/cgi/content/full/117/4/e717
7. Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999;103(2). Available at: www.pediatrics.org/ cgi/content/full/103/2/e14
8. Patel DM, Butler J, Feldman S, Graves GR, Rhodes PG. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr. 1997;131:641-643
9. Linder N, Handsher R, German B, et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed. 2000;83:F24-F27
10. Sood A, Singh D, Mehta S, Midha V, Kumar R. Response to hepatitis B vaccine in preterm babies. Indian J Gastroenterol. 2002;21:52-54
11. Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, Tachibana Yoshida CF, Sandoval de Souza CB. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine. 2002;20:1557-1562
12. O'Shea TM, Dillard RG, Gillis DC, Abramson JS. Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res Reg Aff. 1993;10:49-57
13. D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics. 1995;96:18-22
14. Khalak R, Pichichero ME, D'Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics. 1998;101:597-603
15. Conway S, James J, Balfour A, Smithells R. Immunisation of the preterm baby. J Infect. 1993;27:143-150
16. Kirmani KI, Lofthus G, Pichichero ME, Voloshen T, D'Angio CT. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics. 2002;109:498-504
17. Groothuis JR, Levin MJ, Lehr MV, Weston JA, Hayward AR. Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine. 1992;10:221-225
18. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods. 1981;3:251-260
19. Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 2006;24:683-690
20. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036-1042
21. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol. 1990;32:189-193
22. Centers for Disease Control and Prevention (CDC). Epidemiology of measles - United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2004;53:713-716
23. Centers for Disease Control and Prevention (CDC). Measles - United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54:1229-1231
24. Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of mumps - United States, January 1-May 2, 2006. MMWR Morb Mortal Wkly Rep. 2006;55:559-563
25. Meissner HC, Reef SE, Cochi S. Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics. 2006;117:933-935
26. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics. 2005;116:1287-1291
27. Stein CE, Birmingham M, Kurian M, Duclos P, Strebel P. The global burden of measles in the year 2000: a model that uses country-specific indicators. J Infect Dis. 2003;187(suppl 1):S8-S14
28. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-855
29. Grose C. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. J Clin Virol. 2005;33:89-95; discussion 96-88
30. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J. 2005;24:233-236
31. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005;115:1488-1493
32. Centers for Disease Control and Prevention (CDC). Varicella-related deaths - United States, January 2003-June 2004. MMWR Morb Mortal Wkly Rep. 2005;54:272-274
33. Steele RW, Hensen SA, Vincent MM, Fuccillo DA, Bellanti JA. Development of specific cellular and humoral immune responses in children immunized with live rubella virus vaccine. J Infect Dis. 1974;130:449-453
34. D'Angio CT, Hall CB. Timing of vaccinations in premature infants. BioDrugs. 2000;13:335-346
35. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics. 1985;75:667-671
36. Weibel RE, Kuter BJ, Neff BJ, et al. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA. 1985;254:2435-2439
37. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78:748-756
38. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics. 1988;81:512-518
39. Adenyi-Jones SC, Faden H, Ferdon MB, Kwong MS, Ogra PL. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr. 1992;120:686-689
40. Esposito S, Faldella G, Giammanco A, et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002;20:2928-2932
41. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100
42. Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, Varivax and Tetramune in healthy children vs. concomitant injections of M-M-R II and Tetramune followed six weeks later by Varivax. Pediatr Infect Dis J. 1998;17:980-985
43. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis. 2000;31:973-980